CA3001599A1 - Combination therapy for treating malignancies - Google Patents

Combination therapy for treating malignancies Download PDF

Info

Publication number
CA3001599A1
CA3001599A1 CA3001599A CA3001599A CA3001599A1 CA 3001599 A1 CA3001599 A1 CA 3001599A1 CA 3001599 A CA3001599 A CA 3001599A CA 3001599 A CA3001599 A CA 3001599A CA 3001599 A1 CA3001599 A1 CA 3001599A1
Authority
CA
Canada
Prior art keywords
compound
dose
day
cytarabine
aml
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA3001599A
Other languages
English (en)
French (fr)
Inventor
Samuel V. Agresta
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Agios Pharmaceuticals Inc
Original Assignee
Agios Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Agios Pharmaceuticals Inc filed Critical Agios Pharmaceuticals Inc
Publication of CA3001599A1 publication Critical patent/CA3001599A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/136—Amines having aromatic rings, e.g. ketamine, nortriptyline having the amino group directly attached to the aromatic ring, e.g. benzeneamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
    • A61K31/704—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7048—Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Plural Heterocyclic Compounds (AREA)
CA3001599A 2015-10-15 2016-10-14 Combination therapy for treating malignancies Abandoned CA3001599A1 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201562242256P 2015-10-15 2015-10-15
US62/242,256 2015-10-15
US201562255194P 2015-11-13 2015-11-13
US62/255,194 2015-11-13
PCT/US2016/057083 WO2017066599A1 (en) 2015-10-15 2016-10-14 Combination therapy for treating malignancies

Publications (1)

Publication Number Publication Date
CA3001599A1 true CA3001599A1 (en) 2017-04-20

Family

ID=57208385

Family Applications (1)

Application Number Title Priority Date Filing Date
CA3001599A Abandoned CA3001599A1 (en) 2015-10-15 2016-10-14 Combination therapy for treating malignancies

Country Status (15)

Country Link
US (2) US10905692B2 (cg-RX-API-DMAC7.html)
EP (2) EP4147692A1 (cg-RX-API-DMAC7.html)
JP (2) JP2018534288A (cg-RX-API-DMAC7.html)
KR (2) KR20250065944A (cg-RX-API-DMAC7.html)
CN (1) CN108366980A (cg-RX-API-DMAC7.html)
AU (1) AU2016340087C1 (cg-RX-API-DMAC7.html)
BR (1) BR112018007304A2 (cg-RX-API-DMAC7.html)
CA (1) CA3001599A1 (cg-RX-API-DMAC7.html)
CL (1) CL2018000927A1 (cg-RX-API-DMAC7.html)
EA (1) EA201890968A1 (cg-RX-API-DMAC7.html)
IL (2) IL311873A (cg-RX-API-DMAC7.html)
MX (2) MX394796B (cg-RX-API-DMAC7.html)
SG (1) SG10201912886XA (cg-RX-API-DMAC7.html)
WO (1) WO2017066599A1 (cg-RX-API-DMAC7.html)
ZA (1) ZA201802088B (cg-RX-API-DMAC7.html)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2962943A1 (en) 2014-09-29 2016-04-07 Agios Pharmaceuticals, Inc. Therapeutically active compounds and their methods of use
CA2975506A1 (en) 2015-02-04 2016-08-11 Agios Pharmaceuticals, Inc. Therapeutically active compounds and their methods of use
KR102701893B1 (ko) 2015-10-15 2024-09-03 셀진 코포레이션 악성종양을 치료하기 위한 조합 요법
US12064445B2 (en) 2015-12-03 2024-08-20 Biosight Ltd. Cytarabine conjugates for cancer therapy
BR112019004356A2 (pt) 2016-09-07 2019-05-28 Celgene Corporation composições de comprimido
WO2018204787A1 (en) 2017-05-05 2018-11-08 Memorial Sloan Kettering Cancer Center Methods of treatment of myeloproliferative neoplasm
CN110869029A (zh) * 2017-07-09 2020-03-06 拜欧赛特有限公司 组合癌症治疗
US10980788B2 (en) * 2018-06-08 2021-04-20 Agios Pharmaceuticals, Inc. Therapy for treating malignancies
WO2020092894A1 (en) 2018-11-02 2020-05-07 Celgene Corporation Solid forms of 2-methyl-1-[(4-[6-(trifluoromethyl) pyridin-2-yl]-6-{[2-(trifluoromethyl)pyridin-4-yl]amino}-1,3,5-triazin-2-yl) amino]propan-2-ol
WO2020092906A1 (en) 2018-11-02 2020-05-07 Celgene Corporation Co-crystals of 2-methyl-1 -[(4-[6-(trifluoromethyl)pyridin-2-yl]-6-{[2-(trifluoromethyl) pyridin-4-yl]amino}-1,3,5-triazin-2-yl)amino]propan-2-ol, compositions and methods of use thereof
WO2020092915A1 (en) 2018-11-02 2020-05-07 Celgene Corporation Solid dispersions for treatment of cancer
EP4058028B1 (en) 2019-11-14 2025-03-05 Celgene Corporation Pediatric formulations for treatment of cancer
CN111087408B (zh) * 2020-01-03 2021-04-02 浙江大学 一种大环结构的idh2突变体抑制剂及其医药用途

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998055107A1 (en) 1997-06-06 1998-12-10 Depomed, Inc. Gastric-retentive oral drug dosage forms for controlled release of highly soluble drugs
US6635280B2 (en) 1997-06-06 2003-10-21 Depomed, Inc. Extending the duration of drug release within the stomach during the fed mode
AU767812B2 (en) 2000-02-04 2003-11-27 Depomed, Inc. Shell-and-core dosage form approaching zero-order drug release
US6723340B2 (en) 2001-10-25 2004-04-20 Depomed, Inc. Optimal polymer mixtures for gastric retentive tablets
JP6067226B2 (ja) 2009-03-13 2017-01-25 アジオス ファーマシューティカルズ， インコーポレイテッド 細胞増殖関連疾患のための方法および組成物
CA2793836C (en) * 2009-10-21 2020-03-24 Agios Pharmaceuticals, Inc. Methods and compositions for cell-proliferation-related disorders
EP4647076A2 (en) 2012-01-06 2025-11-12 Les Laboratoires Servier Therapeutically active compounds and their methods of use
AU2014287122B9 (en) 2013-07-11 2018-11-01 Les Laboratoires Servier N,6-bis(aryl or heteroaryl)-1,3,5-triazine-2,4-diamine compounds as IDH2 mutants inhibitors for the treatment of cancer
PE20160840A1 (es) 2013-08-02 2016-09-22 Agios Pharmaceuticals Inc Formas cristalinas de compuestos inhibidores de isocitrato deshidrogenasa 2 (idh2)
WO2015018060A1 (en) 2013-08-09 2015-02-12 Agios Pharmaceuticals, Inc. Crystalline forms of therapeutically active compounds and use thereof
CA2962943A1 (en) 2014-09-29 2016-04-07 Agios Pharmaceuticals, Inc. Therapeutically active compounds and their methods of use
CA2975506A1 (en) 2015-02-04 2016-08-11 Agios Pharmaceuticals, Inc. Therapeutically active compounds and their methods of use
US9751863B2 (en) 2015-08-05 2017-09-05 Agios Pharmaceuticals, Inc. Therapeutically active compounds and their methods of use
KR102701893B1 (ko) 2015-10-15 2024-09-03 셀진 코포레이션 악성종양을 치료하기 위한 조합 요법
EP3383433A1 (en) 2015-12-04 2018-10-10 Agios Pharmaceuticals, Inc. Methods of treatment of malignancies
CA3015757A1 (en) 2016-02-26 2017-08-31 Agios Pharmaceuticals, Inc. Idh1 inhibitors for the treatment of haematological malignancies and solid tumours

Also Published As

Publication number Publication date
BR112018007304A2 (pt) 2018-10-23
KR20180063125A (ko) 2018-06-11
AU2016340087A1 (en) 2018-04-12
JP2021130682A (ja) 2021-09-09
EP4147692A1 (en) 2023-03-15
MX2022006701A (es) 2022-07-12
MX2018004595A (es) 2019-07-04
EA201890968A1 (ru) 2018-09-28
IL258269A (en) 2018-05-31
KR20250065944A (ko) 2025-05-13
EP3362057A1 (en) 2018-08-22
IL311873A (en) 2024-06-01
US20210386749A1 (en) 2021-12-16
US20180311249A1 (en) 2018-11-01
ZA201802088B (en) 2021-07-28
JP2018534288A (ja) 2018-11-22
WO2017066599A1 (en) 2017-04-20
SG10201912886XA (en) 2020-02-27
AU2016340087C1 (en) 2022-08-18
AU2016340087B2 (en) 2022-05-12
US10905692B2 (en) 2021-02-02
CN108366980A (zh) 2018-08-03
CL2018000927A1 (es) 2018-09-14
MX394796B (es) 2025-03-24
NZ740792A (en) 2024-05-31

Similar Documents

Publication Publication Date Title
US20210386749A1 (en) Combination therapy for treating malignancies
AU2016340098B2 (en) Combination therapy for treating malignancies
US10730854B2 (en) Therapeutically active compounds and their methods of use
AU2016393869B2 (en) IDH2 inhibitors for the treatment of haematological maligancies and solid tumours
US10434105B2 (en) Therapeutically active compounds and their methods of use
US20170157132A1 (en) Methods of treatment of malignancies
EP3493809B1 (en) Enasidenib for treatment of myelodysplastic syndrome
JP7093764B2 (ja) 骨髄異形成症候群の治療方法

Legal Events

Date Code Title Description
FZDE Discontinued

Effective date: 20230104

FZDE Discontinued

Effective date: 20230104